Pfizer virus vaccine on track for regulatory review in October

The companies said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants. The companies are continuing to analyze data from the Phase 1 trials in the U.S. and Germany, they said in a statement.

from Hindustan Times - world https://bit.ly/32cXgFK
https://ift.tt/2zbki14